Literature DB >> 27179189

Determination of dexmedetomidine in children's plasma by ultra-performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study.

Hua-Cheng Liu1, Wei Sun2, Cheng-Yu Wang3, Wei-Yang Ying1, Li-Dan Zheng1, Rui-Feng Zeng1, Zhe Wang2, Ren-Shan Ge4.   

Abstract

A rapid, sensitive, and selective ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of dexmedetomidine in children's plasma. Sample preparation was accomplished through a simple one-step deproteinization procedure with 0.2mL of acetonitrile to a 0.1mL plasma sample. Plasma samples were separated by UPLC on an Acquity UPLC BEH C18 column using a mobile phase consisting of acetonitrile-0.1% formic acid in water with gradient elution. The total run time was 3.1min and the elution of dexmedetomidine was at 1.24min. The detection was performed on a triple quadrupole tandem mass spectrometer in the multiple reaction-monitoring mode using the respective transitions m/z 201.3→95.1 for dexmedetomidine and m/z 204.2→98.0 for the internal standard, respectively. The calibration curve was linear over the range of 0.05-10ng/mL with a lower limit of quantitation of 0.05ng/mL. Mean recovery rate of dexmedetomidine in plasma was in the range of 86.7-89.1%. Intra-day and inter-day precision were both <11.6%. This method was successfully applied in pharmacokinetic study after commencement of 1.0μg/kg dexmedetomidine infusion in children.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Children’s plasma; Dexmedetomidine; Pharmacokinetics; UPLC–MS/MS

Mesh:

Substances:

Year:  2016        PMID: 27179189     DOI: 10.1016/j.jchromb.2016.04.051

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Simultaneous detection of a panel of nine sedatives and metabolites in plasma from critically ill pediatric patients via UPLC-MS/MS.

Authors:  Jonathan Birabaharan; Raymond E West; Thomas D Nolin; Chani Traube; Michael J Bell; Philip E Empey
Journal:  J Pharm Biomed Anal       Date:  2022-05-23       Impact factor: 3.571

2.  Effects of Midazolam on the Development of Adult Leydig Cells From Stem Cells In Vitro.

Authors:  Xingyi Zhao; Minpeng Ji; Xin Wen; Dan Chen; Fu Huang; Xiaoju Guan; Jing Tian; Jiajia Xie; Jingjing Shao; Jiexia Wang; Luoqi Huang; Han Lin; Leping Ye; Haolin Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-12       Impact factor: 5.555

3.  Determination of blood dexmedetomidine in dried blood spots by LC-MS/MS to screen therapeutic levels in paediatric patients.

Authors:  Liliana Rivera-Espinosa; Alejandra Toledo-López; Juan Luis Chávez-Pacheco; Radamés Alemón-Medina; Josefina Gómez-Garduño; Gustavo Lugo-Goytia; Raquel García-Álvarez; Hugo Juárez-Olguín; Luz María Torres-Espíndola; María-Gabriela Pérez-Guillé
Journal:  PLoS One       Date:  2019-01-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.